CTLA4 and B-cell chronic lymphocytic leukemia: In particular, treatment with ibrutinib was shown to downregulate checkpoint inhibitors PD-1 and CTLA-4 in T cells, decrease the Treg/CD4 + T cell ratio as well as diminish the immunosuppressive properties of the CLL cells [46].